Join the Oncology Voice Network. Join for Free
Prepare to LAUNCH: How to Build an MSL Team From Scratch
MSL team building drug launch strategy medical science liaison recruitment field medical team best practices MSL training phases

Prepare to LAUNCH: How to Build an MSL Team From Scratch


Share This Article


Summary

In episode 152, Tom Caravela is joined by John Caskey to delve into the intricacies of assembling the ideal MSL team for a successful drug launch. The discussion covers strategic timing, the importance of leadership, and the sequence of hiring MSLs. Operational requirements such as team size, territory allocation, and KOL support management are explored, alongside the recruiting timeline. The episode highlights key skills and criteria essential for selecting MSLs and emphasizes the need for comprehensive training, detailing how to balance different training phases. The conversation wraps up with a summary of best practices for building an effective field medical team.

Tom Caravela, Managing Partner at The Carolan Group and Host of the MSL Talk Podcast, is interviewed by Jon Kaskey on how to build an MSL team in preparation for a drug launch.
Tom shares….

👉 How early should companies consider hiring MSLs
👉 Who spearheads the process for building out the team
👉 What factors go into determining the number of MSLs per team
👉 How are territories aligned and allocated
👉 What other factors need to be considered for internal medical affairs preparedness

Click for Source
MSL team building, drug launch strategy, medical science liaison recruitment, field medical team best practices, MSL training phases

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Where Did My Interview Go Wrong?
Partner Avatar Tom Caravela

Where Did My Interview Go Wrong?

Article
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Explore OVN